Pesquisar
Enlivex Therapeutics Ltd
ENLVAdicionar à lista de desejos
1.580USD
0.0000.00%
Horário de mercado （ET）Cotações atrasadas em 15 min
25.00MValor de mercado
0.06P/L TTM
Mais detalhes de Enlivex Therapeutics Ltd Empresa
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Enlivex Therapeutics Ltd Perfil
Código da empresaENLV
Nome da EmpresaEnlivex Therapeutics Ltd
Data de listagemJul 30, 2014
CEOHershkovitz (Oren)
Número de funcionários36
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 30
Endereço14 Einstein St.
CidadeNESS-ZIONA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal7403618
Telefone97286623301
Sitehttps://www.enlivex.com/
Código da empresaENLV
Data de listagemJul 30, 2014
CEOHershkovitz (Oren)
Executivos da empresa Enlivex Therapeutics Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Mr. Sangwoo Lee
Mr. Sangwoo Lee
Director
Director
--
--
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Perguntas frequentes
Quem são os cinco principais acionistas de Enlivex Therapeutics Ltd?
Os cinco principais acionistas de Enlivex Therapeutics Ltd são: Mr. Shai A. Novik
Quantas instituições possuem ações da Enlivex Therapeutics Ltd (ENLV)?
Em 2026Q1, 44 instituições possuíam ações da Enlivex Therapeutics Ltd, com valor de mercado aproximado de 2.13M, representando 0.89% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1519291.00.